BN
BRAIN Biotech AG
BNN.DE · XETRA
2.90 € -3.01% (-0.09 €)
1M +6.41%
Market Cap 61.8M €
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
1.52 €
47.6% downside
Current Price
2.9 €
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BNN.DE is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/S 1.05x
P/FCF N/A
P/B N/A
Growth
16 /100
Declining Book val. growth 60.40%
Rev. growth 0.08%
FCF growth N/A
Profitability
4 /100
Weak FCF margin 15.23%
Op. margin 16.69%
Gross margin 15.94%
Quality
17 /100
Poor ROA 23.27%
Asset turnover 0.94x
ROIC 18.44%
Debt
30 /100
High Int. coverage -4.49x
Current ratio 1.44x
Net debt/EBITDA N/A
Stability
82 /100
Stable Profitable years 0
EPS volatility 14.67%
Beta 0.62x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BNN.DE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Adriaan Moelker
Employees
280
Headquarters
Zwingenberg